1. 2015 EASD In Review: CV Risk management in t2dm

2. Program Overview

3. EASD Annual Meeting

4. T2DM and CVD

5. Research at EASD Related to T2DM and CV Risk

6. Research at EASD Related to T2DM and CV Risk

7. Amelioration of Hyperglycemia With SGLT2 Inhibition Prevents Atherosclerosis in Diabetic Mice Independent of Insulin Action

8. Increased Risk of CV-related Events With SUs Compared To Other Antihyperglycemic Drugs

9. Increased Risk of CV-related Events With SUs Compared With Other Antihyperglycemic Drugs (cont)

10. Second-line Treatment With SUs vs DPP-4 Inhibitors Is Associated With Risk of CVD, All-cause Mortality and Severe Hypoglycemia

11. Adjusted Risk of Fatal/Nonfatal CVD in Patients on Second-Line Treatment With MET + SU vs MET + DPP-4

12. Treatment Characteristics and Outcomes With SU vs MET in Incident T2DM: Results of the German CREST Study

13. German CREST Study: Study Population Treatment Characteristics

14. German CREST Study: Patient Outcomes

15. No Difference In MACE With BIL vs Comparator Insulins In T1DM or T2DM

16. Summary of HRs for MACE-plus Events by Study

17. EMPA-REG OUTCOME Study: Empagliflozin, CV Outcomes, and Mortality in T2DM

18. EMPA-REG OUTCOME: Trial Design

19. EMPA-REG OUTCOME: Primary Endpoint, 3-Point MACE*

20. EMPA-REG OUTCOME: CV Death

21. EMPA-REG OUTCOME: CV Death By Treatment Group

22. EMPA-REG OUTCOME: CV Death, MI, and Stroke

23. EMPA-REG OUTCOME: All-cause Mortality

24. EMPA-REG OUTCOME: Hospitalizations for HF

25. EMPA-REG OUTCOME Study: Summary

26. Ongoing CV Outcomes Trials for New Antihyperglycemic Agents

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)